BiotechTube

Ensitrelvir

Phase 2Active
0 watching 0 views this week⚡ Active
52
Hype Score

Development Stage

✓
Pre-clinical
✓
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Long COVID

Conditions

Long COVID, Post Acute Sequelae of COVID-19, Post-Acute COVID-19

Trial Timeline

Apr 9, 2024 → Dec 31, 2025

NCT ID
NCT06161688

About Ensitrelvir

Ensitrelvir is a phase 2 stage product being developed by Shionogi for Long COVID. The current trial status is active. This product is registered under clinical trial identifier NCT06161688. Target conditions include Long COVID, Post Acute Sequelae of COVID-19, Post-Acute COVID-19.

Hype Score Breakdown

Clinical
17
Activity
12
Company
10
Novelty
5
Community
5

Clinical Trials (2)

NCT IDPhaseStatus
NCT06775730Phase 1Completed
NCT06161688Phase 2Active

Competing Products

16 competing products in Long COVID

See all competitors
ProductCompanyStageHype Score
TBM100NovartisApproved
85
GS-6615 + Placebo to match GS-6615 + Placebo to match dofetilide + DofetilideGilead SciencesPhase 1
32
EleclazineGilead SciencesPhase 1
32
EleclazineGilead SciencesPhase 1
32
Placebo + RanolazineGilead SciencesPhase 2
51
GS-6615Gilead SciencesPhase 1
32
Eleclazine + Eleclazine placeboGilead SciencesPhase 3
76
Nirmatrelvir + Ritonavir + PlaceboPfizerPhase 2
51
Staccato alprazolamUCBPhase 3
74
Staccato alprazolamUCBPhase 3
74
N-803 (IL-15 Superagonist)ImmunityBioPhase 2
49
AnktivaImmunityBioPhase 2
49
UX007Ultragenyx PharmaceuticalPhase 2
47
triheptanoinUltragenyx PharmaceuticalPre-clinical
18
TriheptanoinUltragenyx PharmaceuticalPhase 3
72
TriheptanoinUltragenyx PharmaceuticalPre-clinical
18

Other Products from Shionogi

Naldemedine + PlaceboApproved
85
Rosuvastatin + HMG CoA inhibitorApproved
85
StatinApproved
85
CefiderocolApproved
85
Duloxetine + Pregabalin + PlaceboApproved
85